Publication | Open Access

The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers

Tumor BiologyVitro Experimental ModelBreast OncologyOncologyTriple-negative Breast CancersMedicineCancer Cell BiologyBreast CancerAnti-cancer AgentCancer TreatmentPharmacologyCell BiologyCancer ResearchCancer Growth